Wednesday, October 2, 2013
• Aerial Biopharma LLC, of Morrisville, N.C., reported results from a 12-week, 93-patient Phase IIb study of ADX-NO5 in with excessive daytime sleepiness associated with narcolepsy, which the company said validates data from a Phase IIa proof-of-concept trial in a larger patient population with a longer duration of treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.